Cargando…
Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies
BACKGROUND: The COVID-19 pandemic has highlighted disparities in healthcare, particularly in the United States, even though disparities have existed since the organization of the modern healthcare system. Recruitment of patients from racial and ethnic minority groups is often minimal in phase 3 clin...
Autores principales: | Craig, Timothy J., Zaragoza-Urdaz, Rafael H., Li, H. Henry, Yu, Ming, Ren, Hong, Juethner, Salomé, Anderson, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508782/ https://www.ncbi.nlm.nih.gov/pubmed/36153561 http://dx.doi.org/10.1186/s13223-022-00721-y |
Ejemplares similares
-
Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020) -
Lanadelumab for hereditary angioedema
Publicado: (2022) -
Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study
por: Johnston, Douglas T., et al.
Publicado: (2021) -
Pharmacokinetics, Pharmacodynamics, and Exposure‐Response of Lanadelumab for Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020) -
Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab
por: Wong, Jane C.Y., et al.
Publicado: (2023)